ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development,
manufacture and sale of innovative medical devices used in infusion
therapy and critical care applications, today announced financial
results for the quarter ended March 31, 2018.
First Quarter 2018 Results
First quarter 2018 revenue was $372.0 million, compared to
$247.7 million in the same period last year. GAAP gross profit for
the first quarter of 2018 was $149.0 million, as compared to $88.9
million in the same period last year. GAAP gross margin for
the first quarter of 2018 was 40%, as compared to 36% in the same
period last year. GAAP net income for the first quarter of
2018 was $4.9 million, or $0.23 per diluted share, as compared to
GAAP net income of $55.9 million, or $2.86 per diluted share, for
the first quarter of 2017. Adjusted diluted earnings per
share for the first quarter of 2018 were $2.26 as compared to $1.68
for the first quarter of 2017. Also, adjusted EBITDA was
$73.4 million for the first quarter of 2018 as compared to $50.1
million for the first quarter of 2017.
Adjusted EBITDA and adjusted diluted earnings per share are
measures calculated and presented on the basis of methodologies
other than in accordance with GAAP. Please refer to the Use of
Non-GAAP Financial Information following the financial statements
herein for further discussion and reconciliations of these measures
to GAAP measures.
Vivek Jain, ICU Medical's Chief Executive Officer, said, "First
quarter revenues, adjusted EBITDA and adjusted diluted earnings per
share were slightly above our expectations.”
|
Revenues by product line for the three months ended March
31, 2018 and 2017 were as follows (in millions): |
|
|
|
Three months ended |
|
|
|
|
|
|
March 31, |
|
|
|
|
|
|
|
|
|
|
|
|
% |
Product Line |
|
2018 |
|
2017 |
|
$ Change |
|
Change |
Infusion
Consumables |
|
$ |
119.9 |
|
|
$ |
75.7 |
|
|
$ |
44.2 |
|
|
58.4 |
% |
IV Solutions* |
|
144.4 |
|
|
97.4 |
|
|
47.0 |
|
|
48.3 |
% |
Infusion Systems |
|
93.4 |
|
|
46.7 |
|
|
46.7 |
|
|
100.0 |
% |
Critical Care |
|
14.3 |
|
|
12.4 |
|
|
1.9 |
|
|
15.3 |
% |
Other |
|
— |
|
|
15.5 |
|
|
(15.5 |
) |
|
(100.0 |
)% |
|
|
$ |
372.0 |
|
|
$ |
247.7 |
|
|
$ |
124.3 |
|
|
50.2 |
% |
|
*IV
Solutions includes $18.1 million and $14.7 million of contract
manufacturing to Pfizer for the three months ended March 31, 2018
and 2017, respectively. |
|
Conference Call
The Company will host a conference call to discuss first quarter
2018 financial results today at 4:30 p.m. EDT (1:30 p.m.
PDT). The call can be accessed at (800) 936-9761,
international (408) 774-4587, conference ID 3029969. The
conference call will be simultaneously available by webcast, which
can be accessed by going to the Company's website at
www.icumed.com, clicking on the Investors tab, clicking on the
Webcast icon and following the prompts. The webcast will also be
available by replay.
About ICU Medical, Inc.
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells
innovative medical products used in infusion therapy and critical
care applications. ICU Medical's product portfolio includes IV
smart pumps, sets, connectors, closed system transfer devices for
hazardous drugs, sterile IV solutions, cardiac monitoring systems,
along with pain management and safety software technology designed
to help meet clinical, safety and workflow goals. ICU Medical is
headquartered in San Clemente, California. More information about
ICU Medical, Inc. can be found at www.icumed.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements contain words such as "will," "expect,"
"believe," "could," "would," "estimate," "continue," "build,"
"expand" or the negative thereof or comparable terminology, and may
include (without limitation) information regarding the Company's
expectations, goals or intentions regarding the future. These
forward-looking statements are based on management's current
expectations, estimates, forecasts and projections about the
Company and assumptions management believes are reasonable, all of
which are subject to risks and uncertainties that could cause
actual results and events to differ materially from those stated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, decreased demand for the Company's
products, decreased free cash flow, the inability to recapture
conversion delays or part/resource shortages on anticipated timing,
or at all, changes in product mix, increased competition from
competitors, lack of continued growth or improving efficiencies,
unexpected changes in the Company's arrangements with its largest
customers and the Company’s ability to meet expectations regarding
the integration of the Hospira infusion systems business. Future
results are subject to risks and uncertainties, including the risk
factors, and other risks and uncertainties, described in the
Company's filings with the Securities and Exchange Commission,
which include those in the Annual Report on Form 10-K for the year
ended December 31, 2017 and our subsequent filings. Forward-looking
statements contained in this press release are made only as of the
date hereof, and the Company undertakes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events or otherwise.
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED BALANCE
SHEETS |
(In thousands, except par value data) |
|
|
|
March 31, |
|
|
|
|
December 31, |
|
|
2018 |
|
|
|
|
2017 |
|
|
(Unaudited) |
|
|
|
|
(1) |
ASSETS |
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
254,536 |
|
|
|
|
|
$ |
290,072 |
|
Short-term investment securities |
|
14,180 |
|
|
|
|
|
10,061 |
|
TOTAL
CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES |
|
268,716 |
|
|
|
|
|
300,133 |
|
Accounts
receivable, net of allowance for doubtful accounts of $3,839 at
March 31, 2018 and $3,311 at December 31, 2017 |
|
123,477 |
|
|
|
|
|
112,696 |
|
Inventories |
|
295,548 |
|
|
|
|
|
288,657 |
|
Prepaid
income taxes |
|
16,111 |
|
|
|
|
|
10,594 |
|
Prepaid
expenses and other current assets |
|
32,406 |
|
|
|
|
|
41,286 |
|
Related-party receivable |
|
132,272 |
|
|
|
|
|
98,807 |
|
Assets
held-for-sale |
|
— |
|
|
|
|
|
12,489 |
|
TOTAL
CURRENT ASSETS |
|
868,530 |
|
|
|
|
|
864,662 |
|
PROPERTY AND EQUIPMENT,
net |
|
407,582 |
|
|
|
|
|
398,684 |
|
LONG-TERM INVESTMENT
SECURITIES |
|
9,896 |
|
|
|
|
|
14,579 |
|
GOODWILL |
|
12,314 |
|
|
|
|
|
12,357 |
|
INTANGIBLE ASSETS,
net |
|
136,645 |
|
|
|
|
|
143,753 |
|
DEFERRED INCOME
TAXES |
|
20,073 |
|
|
|
|
|
24,775 |
|
OTHER ASSETS |
|
37,702 |
|
|
|
|
|
38,141 |
|
TOTAL
ASSETS |
|
$ |
1,492,742 |
|
|
|
|
|
$ |
1,496,951 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
CURRENT
LIABILITIES: |
|
|
|
|
|
|
|
Accounts
payable |
|
$ |
82,195 |
|
|
|
|
|
$ |
78,228 |
|
Accrued
liabilities |
|
116,448 |
|
|
|
|
|
132,064 |
|
TOTAL
CURRENT LIABILITIES |
|
198,643 |
|
|
|
|
|
210,292 |
|
CONTINGENT EARN-OUT
LIABILITY |
|
23,000 |
|
|
|
|
|
27,000 |
|
OTHER LONG-TERM
LIABILITIES |
|
35,074 |
|
|
|
|
|
55,326 |
|
DEFERRED INCOME
TAXES |
|
1,482 |
|
|
|
|
|
1,487 |
|
INCOME TAX
LIABILITY |
|
4,592 |
|
|
|
|
|
4,592 |
|
COMMITMENTS AND
CONTINGENCIES |
|
— |
|
|
|
|
|
— |
|
STOCKHOLDERS’
EQUITY: |
|
|
|
|
|
|
|
Convertible preferred stock, $1.00 par value Authorized—500 shares;
Issued and outstanding— none |
|
— |
|
|
|
|
|
— |
|
Common
stock, $0.10 par value — Authorized, 80,000 shares; Issued 20,317
shares at March 31, 2018 and 20,210 shares at December 31, 2017;
Outstanding, 20,304 shares at March 31, 2018 and 20,210 shares
at December 31, 2017 |
|
2,032 |
|
|
|
|
|
2,021 |
|
Additional paid-in capital |
|
632,012 |
|
|
|
|
|
625,568 |
|
Treasury
stock, at cost |
|
(3,176 |
) |
|
|
|
|
— |
|
Retained
earnings |
|
596,829 |
|
|
|
|
|
585,624 |
|
Accumulated other comprehensive loss |
|
2,254 |
|
|
|
|
|
(14,959 |
) |
TOTAL
STOCKHOLDERS' EQUITY |
|
1,229,951 |
|
|
|
|
|
1,198,254 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY |
|
$ |
1,492,742 |
|
|
|
|
|
$ |
1,496,951 |
|
|
(1) December 31, 2017 balances were derived from audited
consolidated financial statements. |
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) |
(In thousands, except per share data) |
|
|
Three months ended |
|
March 31, |
|
2018 |
|
2017 |
REVENUE: |
|
|
|
Net
sales |
$ |
372,033 |
|
|
$ |
231,788 |
|
Other |
— |
|
|
15,951 |
|
TOTAL REVENUE |
372,033 |
|
|
247,739 |
|
COST OF GOODS SOLD |
223,032 |
|
|
158,794 |
|
GROSS
PROFIT |
149,001 |
|
|
88,945 |
|
OPERATING
EXPENSES: |
|
|
|
Selling,
general and administrative |
86,997 |
|
|
64,886 |
|
Research
and development |
12,586 |
|
|
11,641 |
|
Restructuring, strategic transaction and integration |
21,569 |
|
|
29,401 |
|
Change in
fair value of contingent earn-out |
(4,000 |
) |
|
— |
|
Contract
settlement |
28,917 |
|
|
— |
|
TOTAL OPERATING
EXPENSES |
146,069 |
|
|
105,928 |
|
INCOME (LOSS) FROM
OPERATIONS |
2,932 |
|
|
(16,983 |
) |
BARGAIN PURCHASE
GAIN |
— |
|
|
63,237 |
|
INTEREST EXPENSE |
(135 |
) |
|
(513 |
) |
OTHER INCOME |
1,026 |
|
|
107 |
|
INCOME BEFORE INCOME
TAXES |
3,823 |
|
|
45,848 |
|
BENEFIT FOR INCOME
TAXES |
1,052 |
|
|
10,015 |
|
NET INCOME |
$ |
4,875 |
|
|
$ |
55,863 |
|
NET INCOME PER
SHARE |
|
|
|
Basic |
$ |
0.24 |
|
|
$ |
3.03 |
|
Diluted |
$ |
0.23 |
|
|
$ |
2.86 |
|
WEIGHTED AVERAGE NUMBER
OF SHARES |
|
|
|
Basic |
20,255 |
|
|
18,439 |
|
Diluted |
21,400 |
|
|
19,549 |
|
Use of Non-GAAP Financial Information
This press release contains financial measures that are not
calculated in accordance with U.S. generally accepted accounting
principles ("GAAP"). The non-GAAP financial measures should
be considered supplemental to, and not as a substitute for, or
superior to, financial measures calculated in accordance with
GAAP. There are material limitations in using these non-GAAP
financial measures because they are not prepared in accordance with
GAAP and may not be comparable to similarly titled non-GAAP
financial measures used by other companies, including peer
companies. Our management believes that the non-GAAP data
provides useful supplemental information to management and
investors regarding our performance and facilitates a more
meaningful comparison of results of operations between current and
prior periods. We use non-GAAP financial measures in addition
to and in conjunction with GAAP financial measures to analyze and
assess the overall performance of our business, in making
financial, operating and planning decisions, and in determining
executive incentive compensation. The non-GAAP financial
measures included in this press release are adjusted EBITDA and
adjusted diluted earnings per share ("Adjusted Diluted EPS").
Adjusted EBITDA excludes the following items from net
income:
Interest, net: We exclude interest in deriving adjusted
EBITDA as interest can vary significantly among companies depending
on a company's level of income generating instruments and/or level
of debt.
Stock compensation expense: Stock-based compensation is
generally fixed at the time the stock-based instrument is granted
and amortized over a period of several years. The value of
stock options is determined using a complex formula that
incorporates factors, such as market volatility, that are beyond
our control. The value of our restricted stock awards is
determined using the grant date stock price, which may not be
indicative of our operational performance over the expense
period. Additionally, in order to establish the fair value of
performance-based stock awards, which are currently an element of
our ongoing stock-based compensation, we are required to apply
judgment to estimate the probability of the extent to which
performance objectives will be achieved. Based on the above
factors, we believe it is useful to exclude stock-based
compensation in order to better understand our operating
performance.
Intangible asset amortization expense: We do not acquire
businesses or capitalize certain patent costs on a predictable
cycle. The amount of purchase price allocated to intangible
assets and the term of amortization can vary significantly and are
unique to each acquisition. Capitalized patent costs can vary
significantly based on our current level of development
activities. We believe that excluding amortization of
intangible assets provides the users of our financial statements
with a consistent basis for comparison across accounting
periods.
Depreciation expense: We exclude depreciation expense in
deriving adjusted EBITDA because companies utilize productive
assets of different ages and the depreciable lives can vary
significantly resulting in considerable variability in depreciation
expense among companies.
Restructuring, strategic transaction and integration: We
incur restructuring and strategic transaction charges that result
from events, which arise from unforeseen circumstances and/or often
occur outside of the ordinary course of our ongoing business.
Although these events are reflected in our GAAP financial
statements, these unique transactions may limit the comparability
of our ongoing operations with prior and future periods.
Adjustment to reverse the cost recognition related to the
purchase accounting write-up of inventory to fair market value: The
inventory step-up represents the expense recognition of fair value
adjustments in excess of the historical cost basis of inventory
obtained through acquisition, these charges are outside of our
normal operations and are excluded.
Bargain purchase gain: We may incur a bargain purchase
gain on certain acquisitions if the fair market value of the
identifiable assets acquired and liabilities assumed, net of
deferred taxes exceeds the total consideration paid. We
exclude such gains as they are related to acquisitions and have no
direct correlation to the operation of our ongoing business.
Contract settlement: Occasionally, we are involved in
contract renegotiations that may result in one-time settlements. We
exclude these settlements as they have no direct correlation to the
operation of our ongoing business.
Change in fair value of contingent earn-out: We exclude
the impact of certain amounts recorded in connection with business
combinations. We exclude items that are either non-cash or
not normal, recurring operating expenses due to their nature,
variability of amounts, and lack of predictability as to occurrence
and/or timing.
Impairment of assets held for sale: We have excluded the effect
of the impairment on assets held for sale in calculating our
non-GAAP adjusted EBITDA and non-GAAP adjusted earnings per share.
Impairments on assets no longer used in operations are not
reflective of our ongoing business and operating results.
Adjusted Diluted EPS excludes from diluted EPS, net of tax,
interest, net, intangible asset amortization expense, stock
compensation expense, restructuring, strategic transaction and
integration, adjustment to reverse the cost recognition related to
the purchase accounting write-up of inventory to fair market value,
contract settlement, change in fair value of contingent earn-out,
impairment of assets held for sale, bargain purchase gain, which
was tax free and the impact of tax reform. We apply our GAAP
consolidated effective tax rate to our non-GAAP financial measures,
other than when the underlying item has a materially different tax
treatment.
From time to time in the future, there may be other items that
we may exclude if we believe that doing so is consistent with the
goal of providing useful information to investors and
management.
The following tables reconcile our GAAP and non-GAAP financial
measures:
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
Reconciliation of GAAP to Non-GAAP Financial
Measures (Unaudited) |
(In thousands) |
|
|
Adjusted EBITDA |
|
Three months Ended |
|
March 31, |
|
2018 |
|
|
|
|
2017 |
GAAP net income |
$ |
4,875 |
|
|
|
|
|
$ |
55,863 |
|
|
|
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
|
|
|
Interest,
net |
(942 |
) |
|
|
|
|
409 |
|
Stock
compensation expense |
5,462 |
|
|
|
|
|
4,006 |
|
Depreciation and amortization expense |
18,304 |
|
|
|
|
|
11,594 |
|
Restructuring, strategic transaction and integration |
21,569 |
|
|
|
|
|
29,401 |
|
Adjustment to reverse the cost recognition related to the purchase
accounting write-up of inventory to fair market value |
— |
|
|
|
|
|
22,053 |
|
Bargain
purchase gain |
— |
|
|
|
|
|
(63,237 |
) |
Contract
settlement |
28,917 |
|
|
|
|
|
— |
|
Change in
fair value of contingent earn-out |
(4,000 |
) |
|
|
|
|
— |
|
Impairment of assets held for sale |
269 |
|
|
|
|
|
— |
|
Benefit
for income taxes |
(1,052 |
) |
|
|
|
|
(10,015 |
) |
Total non-GAAP
adjustments |
68,527 |
|
|
|
|
|
(5,789 |
) |
|
|
|
|
|
|
|
Adjusted
EBITDA |
$ |
73,402 |
|
|
|
|
|
$ |
50,074 |
|
|
|
Adjusted diluted earnings pershare |
|
Three months ended |
|
March 31, |
|
2018 |
|
|
|
2017 |
GAAP diluted earnings
per share |
$ |
0.23 |
|
|
|
|
$ |
2.86 |
|
|
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
|
|
Interest,
net |
$ |
(0.04 |
) |
|
|
|
$ |
0.02 |
|
Stock
compensation expense |
$ |
0.26 |
|
|
|
|
$ |
0.20 |
|
Amortization expense |
$ |
0.19 |
|
|
|
|
$ |
0.17 |
|
Restructuring, strategic transaction and integration |
$ |
1.01 |
|
|
|
|
$ |
1.50 |
|
Adjustment to reverse the cost recognition related to the purchase
accounting write-up of inventory to fair market value |
$ |
— |
|
|
|
|
$ |
1.13 |
|
Bargain
purchase gain |
$ |
— |
|
|
|
|
$ |
(3.23 |
) |
Contract
settlement |
$ |
1.35 |
|
|
|
|
$ |
— |
|
Change in
fair value of contingent earn-out |
$ |
(0.19 |
) |
|
|
|
$ |
— |
|
Impairment of assets held for sale |
$ |
0.01 |
|
|
|
|
$ |
— |
|
Estimated
income tax impact from adjustments |
$ |
(0.56 |
) |
|
|
|
$ |
(0.97 |
) |
Adjusted diluted
earnings per share |
$ |
2.26 |
|
|
|
|
$ |
1.68 |
|
|
CONTACT:ICU Medical, Inc.Scott Lamb, Chief Financial
Officer(949) 366-2183
ICR, Inc.John Mills, Partner(646) 277-1254
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Apr 2023 to Apr 2024